Purdue Pharma Appoints Dr. Marcelo Bigal as CMO
6 March 2018 - - Stamford, Connecticut-based pharmaceutical company Purdue Pharma L.P. has named Marcelo Bigal, MD, PhD as chief medical officer, the company said.
Bigal will be responsible for general medical governance and patient safety oversight relating to all Purdue products in development and in the market. He will also become part of the senior leadership team that addresses the scientific and medical aspects of the company's product portfolio with government agencies, including the US Food and Drug Administration.
Bigal brings more than 12 years of pharmaceutical experience spanning research and development, clinical operations and innovations, and scientific affairs. He most recently served as chief scientific officer at Teva Pharmaceuticals. Prior to that he served as CMO and head of the clinical development organization, in which he oversaw innovative clinical development (Phases 1 to 3) across all specialty areas. Before joining Teva, Bigal was CMO at Labrys Biologics, Inc.
Bigal holds a Medical Doctorate degree from the College of Medicine at the University of São Paulo, Brazil, where he also obtained a Masters in Science and a PhD in Neurosciences. He completed his post-doctoral research at the New England Center for Headache in Stamford, Conn.
Privately-held Purdue Pharma is part of a network of independent associated companies dedicated to providing patients and providers with innovative medicines. The company's leadership and employees are committed to serving healthcare professionals, patients and caregivers by providing quality products and educational resources.